Contineum Therapeutics, Inc. CTNM
12.56
0.07
0.56%
as of 25 Sep
- Market cap
- $469.9M
- P/E
- 0.0×
Follow CTNM
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
28.68 | 26.98 | 37.00 | 36.25 | |
Current Ratio |
29.07 | 27.50 | 38.00 | 37.17 | |
Net Debt/EBITDA |
12.28 | 15.44 | 14.64 | 13.68 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.95 | 0.86 | 1.13 | 0.76 | |
Capex/Depreciation |
(1.21) | (0.49) | (3.76) | (0.04) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.43) | (0.47) | (0.44) | (0.31) | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.44) | (0.47) | (0.44) | (0.31) | |
Cash per Share |
6.49 | 9.49 | 6.60 | 6.31 | |
Shareholders Equity per Share |
6.42 | 9.42 | 6.70 | 6.40 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.42 | 9.42 | 6.70 | 6.40 | |
Free Cash Flow |
(12.29) | (13.08) | (16.58) | (11.51) | |
Working Capital |
178.57 | 258.17 | 246.31 | 236.05 | |
Capital Expenditures |
(0.10) | (0.04) | (0.31) | (0.01) | |
Net Current Asset Value |
174.55 | 252.26 | 241.66 | 231.87 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
| Other line items | |||||
Average Payables |
1.09 | 1.41 | 2.57 | 1.25 | |
Average Assets |
203.44 | 244.74 | 229.81 | 216.63 | |
Average Common Equity |
195.35 | 229.53 | 217.40 | 205.53 |
Columns are period end dates